Skip to main content
Erschienen in:

20.09.2021 | Parkinson-Krankheit | Zertifizierte Fortbildung Neurologie Zur Zeit gratis

COVID-19

Parkinson-Therapie in der Pandemie

verfasst von: PD Dr. med. Friederike Sixel-Döring, Univ. Prof. Dr. med. Claudia Trenkwalder

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Auszug

Für Parkinson-Patienten mit einer Corona-Virus-Disease 2019 (COVID-19) sind ein höheres Alter, ein fortgeschrittenes Krankheitsstadium, eine erhöhte Gebrechlichkeit sowie Komorbiditäten wie erhöhter Blutdruck, andere kardiovaskuläre Erkrankungen und Diabetes mellitus Risikofaktoren für einen tödlichen Verlauf. Daneben haben Behandlungsbeschränkungen und Auswirkungen der Maßnahmen zur Eindämmung der Pandemie aber auch zu einer Abnahme körperlicher Aktivität und Lebensqualität sowie zu einer Zunahme von Angst und Depression bei Parkinson-Patienten geführt.
Literatur
1.
Zurück zum Zitat Artusi CA, Romagnolo A, Ledda C, Zibetti M, Rizzone MG, Montanaro E, Bozzali M, Lopiano L. COVID-19 and Parkinson's Disease: What Do We Know So Far?. J Parkinsons Dis. 2021;11(2):445-454 Artusi CA, Romagnolo A, Ledda C, Zibetti M, Rizzone MG, Montanaro E, Bozzali M, Lopiano L. COVID-19 and Parkinson's Disease: What Do We Know So Far?. J Parkinsons Dis. 2021;11(2):445-454
2.
Zurück zum Zitat Jakob CEM, Borgmann S, Duygu F, Behrends U et al. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients(LEOSS). Infection 2021; 49:63-73 Jakob CEM, Borgmann S, Duygu F, Behrends U et al. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients(LEOSS). Infection 2021; 49:63-73
3.
Zurück zum Zitat Huber MK, Raichle C, Lingor P, Synofzik M, et al. Outcomes of SARS-CoV-2 Infections in Patients with Neurodegenerative Disease in the LEOSS Cohort. Movement Disord 2021;36: 791-3 Huber MK, Raichle C, Lingor P, Synofzik M, et al. Outcomes of SARS-CoV-2 Infections in Patients with Neurodegenerative Disease in the LEOSS Cohort. Movement Disord 2021;36: 791-3
4.
Zurück zum Zitat Vignatelli L, Zenesini C, Belotti L, Baldin E et al. Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism. Movement Disord 2021; 36: 1-10 Vignatelli L, Zenesini C, Belotti L, Baldin E et al. Risk of Hospitalization and Death for COVID-19 in People with Parkinson's Disease or Parkinsonism. Movement Disord 2021; 36: 1-10
5.
Zurück zum Zitat Scherbaum R, Kwon EH, Richter D, Bartig D et al. Clinical profiles and mortality of COVID-19 inpatients with Parkinson's Disease in Germany. Movement Disord 2021; 36: 1049-57 Scherbaum R, Kwon EH, Richter D, Bartig D et al. Clinical profiles and mortality of COVID-19 inpatients with Parkinson's Disease in Germany. Movement Disord 2021; 36: 1049-57
6.
Zurück zum Zitat Menni C, Valdes AM, Freidin MB, Sudre C et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med.2020; 26:1037-40 Menni C, Valdes AM, Freidin MB, Sudre C et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med.2020; 26:1037-40
7.
Zurück zum Zitat Fasano A, Cereda E, Barichella M, Cassani E et al. COVID-19 in Parkinson's disease patients living in Lombardy, Italy. Movement Disorders 2020; 35: 1089-1093 Fasano A, Cereda E, Barichella M, Cassani E et al. COVID-19 in Parkinson's disease patients living in Lombardy, Italy. Movement Disorders 2020; 35: 1089-1093
8.
Zurück zum Zitat Cilia R, Bonvegna S, Straccia G, Andreasi NG et al. Effects of COVID-19 on Parkinson's Disease clinical features: A community-based case-control study. Movement Disorders 2020; 35:1287-1292 Cilia R, Bonvegna S, Straccia G, Andreasi NG et al. Effects of COVID-19 on Parkinson's Disease clinical features: A community-based case-control study. Movement Disorders 2020; 35:1287-1292
9.
Zurück zum Zitat Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism and Related Disorders 2020; 75:126-7 Hainque E, Grabli D. Rapid worsening in Parkinson's disease may hide COVID-19 infection. Parkinsonism and Related Disorders 2020; 75:126-7
10.
Zurück zum Zitat Fearon C, Fasano A. Parkinson's Disease and the COVID-19 Pandemic. Journal of Parkinson's Disease 2021; 11:431-444 Fearon C, Fasano A. Parkinson's Disease and the COVID-19 Pandemic. Journal of Parkinson's Disease 2021; 11:431-444
11.
Zurück zum Zitat Tarakad A, Jankovic J. Anosmia and ageusia in Parkinson's disease. Int Rev Neurobiol 2017; 133: 541-556 Tarakad A, Jankovic J. Anosmia and ageusia in Parkinson's disease. Int Rev Neurobiol 2017; 133: 541-556
12.
Zurück zum Zitat Yan R, Zhang Y, Li Y, Xia L et al. Structural basis for the recognition of the SARS-CoV-2 by full length human ACE2. Science 2020; 367: 1444-1448 Yan R, Zhang Y, Li Y, Xia L et al. Structural basis for the recognition of the SARS-CoV-2 by full length human ACE2. Science 2020; 367: 1444-1448
13.
Zurück zum Zitat Doobay MF, Talman LS, Obr TD, Tian X et al. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 292: R373-81 Doobay MF, Talman LS, Obr TD, Tian X et al. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 292: R373-81
14.
Zurück zum Zitat Papa SM, Brundin P, Fung VSC, Kang UJ et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders 2020; 35: 711-715 Papa SM, Brundin P, Fung VSC, Kang UJ et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders 2020; 35: 711-715
15.
Zurück zum Zitat Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci 2019; 168: 299-322 Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci 2019; 168: 299-322
16.
Zurück zum Zitat Pavel A, Murray DK, Stoessl J. COVID-19 and selective vulnerability to Parkinson's disease. Lancet Neurol 2020; 19: 719 Pavel A, Murray DK, Stoessl J. COVID-19 and selective vulnerability to Parkinson's disease. Lancet Neurol 2020; 19: 719
17.
Zurück zum Zitat Beatman EL, Massey A, Shives KD et al. Alpha-synuclei expression restricts RNA viral infections in the brain. J Virol 2015; 90: 2767-2782 Beatman EL, Massey A, Shives KD et al. Alpha-synuclei expression restricts RNA viral infections in the brain. J Virol 2015; 90: 2767-2782
18.
Zurück zum Zitat Jang H, Boltz D, Sturm-Ramirez K et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 2009; 106: 14063-14068 Jang H, Boltz D, Sturm-Ramirez K et al. Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 2009; 106: 14063-14068
19.
Zurück zum Zitat Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Movement Disorders 2020; 35: 716-720 Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the crossroad between aging and neurodegeneration. Movement Disorders 2020; 35: 716-720
20.
Zurück zum Zitat Merello M, Bathia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol 2021; 20:94-95 Merello M, Bathia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy. Lancet Neurol 2021; 20:94-95
21.
Zurück zum Zitat Richter D, Scherbaum R, Bartig D, Gold R et al. Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany. Parkinsonism Relat Disord 2021; 85: 109-113 Richter D, Scherbaum R, Bartig D, Gold R et al. Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany. Parkinsonism Relat Disord 2021; 85: 109-113
22.
Zurück zum Zitat Reuter S, Deuschl G, Falk D, Mehdorn M, Witt K. Uncoupling of dopaminergic and subthalamic stimulation: Life-threatening DBS withdrawal syndrome. Movement Disorders 2015; 30: 1407-1413 Reuter S, Deuschl G, Falk D, Mehdorn M, Witt K. Uncoupling of dopaminergic and subthalamic stimulation: Life-threatening DBS withdrawal syndrome. Movement Disorders 2015; 30: 1407-1413
23.
Zurück zum Zitat Azar J, Elinav H, Safadi R, Soliman M. Malignant deep brain stimulator withdrawal syndrome. BMJ Case Rep (2019); 12: e229122 Azar J, Elinav H, Safadi R, Soliman M. Malignant deep brain stimulator withdrawal syndrome. BMJ Case Rep (2019); 12: e229122
24.
Zurück zum Zitat Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson's disease: Hidden sorrows and emerging opportunities. J Parkinson's Disease 2020; 10: 351-354 Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson's disease: Hidden sorrows and emerging opportunities. J Parkinson's Disease 2020; 10: 351-354
25.
Zurück zum Zitat Timmer MHM, van Beek MHCT, Bloem BR, Esselink RAJ. What a neurologist should know about depression in Parkinson's disease. Pract Neurol 2017; 17: 359-368 Timmer MHM, van Beek MHCT, Bloem BR, Esselink RAJ. What a neurologist should know about depression in Parkinson's disease. Pract Neurol 2017; 17: 359-368
26.
Zurück zum Zitat Shalash A, Roushdy T, Essam M, Fathy M et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Movement Disorders 2020; 35: 1-3 Shalash A, Roushdy T, Essam M, Fathy M et al. Mental health, physical activity, and quality of life in Parkinson's disease during COVID-19 pandemic. Movement Disorders 2020; 35: 1-3
27.
Zurück zum Zitat Feeney MP, Xu Y, Surface M, Shah H et al. The impact of COVID-19 and social distancing on people with Parkinson's disease: a survey study. Npj Parkinson's Disease 2021; 7:10 Feeney MP, Xu Y, Surface M, Shah H et al. The impact of COVID-19 and social distancing on people with Parkinson's disease: a survey study. Npj Parkinson's Disease 2021; 7:10
28.
Zurück zum Zitat Baschi R, Luca A, Nicoletti A, Caccamo M et al. Changes in motor, cognitive, and behavioral symptoms in Parkinson's disease and mild cognitive impairment during the COVID-19 lockdown. Frontiers in Psychiatry 2020; 11: 590134 Baschi R, Luca A, Nicoletti A, Caccamo M et al. Changes in motor, cognitive, and behavioral symptoms in Parkinson's disease and mild cognitive impairment during the COVID-19 lockdown. Frontiers in Psychiatry 2020; 11: 590134
29.
Zurück zum Zitat Hanff AM, Pauly C, Pauly L, Schrödder V et al. Unmet needs of people with Parkinson's disease and their caregivers during COVID-19 related confinement: an explorative secondary data analysis. Frontiers in Neurology 2021; 11: 615172 Hanff AM, Pauly C, Pauly L, Schrödder V et al. Unmet needs of people with Parkinson's disease and their caregivers during COVID-19 related confinement: an explorative secondary data analysis. Frontiers in Neurology 2021; 11: 615172
30.
Zurück zum Zitat Santos Garcia D, Oreiro M, Perez P, Fanjul G et al. Impact of COVID-19 pandemic on Parkinson's disease: A cross-sectional survey of 568 Spanish patients. Movement Disorders 2020; 35: 1712-1716 Santos Garcia D, Oreiro M, Perez P, Fanjul G et al. Impact of COVID-19 pandemic on Parkinson's disease: A cross-sectional survey of 568 Spanish patients. Movement Disorders 2020; 35: 1712-1716
31.
Zurück zum Zitat Song J, Ahn JH, Choi I, Mun JK et al. The changes of exercise pattern and clinical symptoms in patientes with Parkinson's disease in the era of COVID-19 pandemic. Parkinsonism Relat disord 2020; 80: 148-151 Song J, Ahn JH, Choi I, Mun JK et al. The changes of exercise pattern and clinical symptoms in patientes with Parkinson's disease in the era of COVID-19 pandemic. Parkinsonism Relat disord 2020; 80: 148-151
32.
Zurück zum Zitat Ehgoetz Martens KA, Hall JM, Georgiades MJ, Gilat M et al. The functional network signature of heterogeneity in freezing of gait. Brain 2018; 141: 1145-1160 Ehgoetz Martens KA, Hall JM, Georgiades MJ, Gilat M et al. The functional network signature of heterogeneity in freezing of gait. Brain 2018; 141: 1145-1160
33.
Zurück zum Zitat Zach H, Dirkx M, Pasman JW, Bloem BR et al. Cognitive stress reduces the effect of levodopa on Parkinson's resting tremor. CNS Neurosci Ther 2017; 23: 209-215 Zach H, Dirkx M, Pasman JW, Bloem BR et al. Cognitive stress reduces the effect of levodopa on Parkinson's resting tremor. CNS Neurosci Ther 2017; 23: 209-215
34.
Zurück zum Zitat Ben-Pazi H, Browne P, Chan P et al. The promise of telemedicine for movement disorders: an interdisciplinary approach. Curr Neurol Neurosci Rep 2018; 18:26 Ben-Pazi H, Browne P, Chan P et al. The promise of telemedicine for movement disorders: an interdisciplinary approach. Curr Neurol Neurosci Rep 2018; 18:26
35.
Zurück zum Zitat Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: The example of Parkinson's disease. Lancet Neurol 2017; 16:541-551 Schneider RB, Biglan KM. The promise of telemedicine for chronic neurological disorders: The example of Parkinson's disease. Lancet Neurol 2017; 16:541-551
36.
Zurück zum Zitat Espay AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J et al. Movement Disorder Society Task Force on Technology. A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders 2019; 34: 657-663 Espay AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J et al. Movement Disorder Society Task Force on Technology. A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. Movement Disorders 2019; 34: 657-663
37.
Zurück zum Zitat Motolese F, Magliozzi A, Puttini F, Rossi M et al. Parkinson's disease patients remote monitoring during the COVID-19 lockdown. Front Neurol 2020; 11: 567413 Motolese F, Magliozzi A, Puttini F, Rossi M et al. Parkinson's disease patients remote monitoring during the COVID-19 lockdown. Front Neurol 2020; 11: 567413
38.
Zurück zum Zitat Eggers C, Wellach I, Groppa S, Strothjohann M, Klucken J. Versorgung von Parkinson-Patienten in Deutschland: Status quo und Perspektiven im Spiegel des digitalen Wandels. Nervenarzt 2020; Nov 16:1-8 Eggers C, Wellach I, Groppa S, Strothjohann M, Klucken J. Versorgung von Parkinson-Patienten in Deutschland: Status quo und Perspektiven im Spiegel des digitalen Wandels. Nervenarzt 2020; Nov 16:1-8
39.
Zurück zum Zitat Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalida LV et al. COVID-19 Vaccination for persons with Parkinson's disease: Light at the end of the tunnel? Journal of Parkinson's Disease 2021; 11: 3-8 Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalida LV et al. COVID-19 Vaccination for persons with Parkinson's disease: Light at the end of the tunnel? Journal of Parkinson's Disease 2021; 11: 3-8
Metadaten
Titel
COVID-19
Parkinson-Therapie in der Pandemie
verfasst von
PD Dr. med. Friederike Sixel-Döring
Univ. Prof. Dr. med. Claudia Trenkwalder
Publikationsdatum
20.09.2021
Verlag
Springer Medizin
Erschienen in
InFo Neurologie + Psychiatrie / Ausgabe 9/2021
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI
https://doi.org/10.1007/s15005-021-2010-9

Weitere Artikel der Ausgabe 9/2021

InFo Neurologie + Psychiatrie 9/2021 Zur Ausgabe

Zertifizierte Fortbildung Psychiatrie

CME: Neuropsychiatrische Post-COVID-Symptome

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Multimodale Intervention verbessert Demenzrisikoprofil

18.07.2024 Demenz Nachrichten

Eine Auswertung der Studie AgeWell.de legt nahe, dass sich auch bei älteren Personen mit hoher Demenzgefahr das Risikoprofil durch Lebensstiländerungen verbessern lässt. Die stärksten Auswirkungen haben dabei eine Ernährungsumstellung und eine gute Blutdruckkontrolle.

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Herzrhythmusstörungen – neue Verfahren für langfristige Erfolge

16.07.2024 Vorhofflimmern Podcast

Prof. Markus Lerch wirft gemeinsam mit dem Herzspezialisten Prof. Gerd Hasenfuß aus Göttingen einen Blick auf neue Entwicklungen in der Diagnostik und Therapie von Herzrhythmusstörungen. Hören Sie in dieser Folge, warum fast jedes Vorhofflimmern therapiert werden sollte, wieso die Ablationsbehandlung auch bei Herzinsuffizienz gute Effekte zeigt und vor und nach welchen Medikamenten Sie ein EKG schreiben sollten.

Deutsche Gesellschaft für Innere Medizin

Transformation im All: Wie Raumfahrt das Gehirn verändert

12.07.2024 Neurologische Diagnostik Nachrichten

Schwerelosigkeit und kosmische Strahlung gehen nicht spurlos am Nervensystem vorbei. Wer ins Weltall fliegt, riskiert langfristige Veränderungen im Gehirn, zum Beispiel in der Flüssigkeitsverteilung.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.